Article Text

Download PDFPDF
Pneumocystis jirovecii pneumonia as a complication of etoposide therapy
  1. Maria Alejandra Mendoza1,
  2. Sunil Iyer2,
  3. Jose F. Camargo3 and
  4. Pasquale W. Benedetto4
  1. 1 Internal Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
  2. 2 Internal Medicine, University of Miami, Miami Beach, Florida, USA
  3. 3 Department of Medicine, Division of Infectious Diseases, University of Miami, Miami, Florida, USA
  4. 4 Deparment of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA
  1. Correspondence to Dr Maria Alejandra Mendoza; maria.mendoza2{at}


Two patients receiving oral etoposide therapy developed Pneumocystis jirovecii pneumonia during chemotherapy with significant lymphopenia without corticosteroid use. In this commentary we discuss cellular mechanisms by which etoposide induced CD4+ T lymphocyte dysfunction and reduced survival may lead to predisposition to P. jirovecii infection.

  • malignant disease and immunosuppression
  • infections
  • haematology (incl blood transfusion)
  • pneumonia (infectious disease)

Statistics from


  • Contributors PAB and MAM conceived of the presented idea. MAM, JC, SI and PAB created manuscript draft. All authors discussed the results and contributed to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.